Erasca announced a $500 million public offering of common stock on July 13, which later closed on July 15 as an upsized offering of 36,142,857 shares at $17.50 per share. Gross proceeds reached approximately $632.5 million following the full exercise of the underwriters' option to purchase additional shares. However, on July 20, The Schall Law Firm announced a class action lawsuit opportunity against Erasca for allegedly misleading the market regarding preclinical data.
The Schall Law Firm invites investors to lead a class action against Erasca for allegedly misleading the market regarding its ERAS-0015 program.
Read the full storyThe biotech firm finalized the sale of over 36 million shares at $17.50 each, leveraging strong institutional demand to expand its therapeutic portfolio.
In a sudden reversal reflecting the high-risk nature of the biotech sector, Erasca is facing a dual crisis that has severely eroded its market valuation.